Jim Davis, M.S., Analytical Chemistry, Analytical and Preformulation Services
Mr. Davis has a M.S. in analytical chemistry from Georgia State University in Atlanta as well as a B.S.A. in biological sciences from the University of Georgia in Athens. With 10 years experience, Mr. Davis has held several positions as an analytical chemist and consultant to the pharmaceutical industry. Prior to forming CoreRx, Mr. Davis served as both a section head and as a senior scientist within the analytical laboratory of MDS Pharma Services in Tampa, FL. Prior to MDS he was a lead scientist in the R&D Nasal Division of Bausch and Lomb in Tampa. He formerly served as a scientist in analytical services for contract research organizations (CROs) Proceutics and Oread in Atlanta. He has extensive experience in the separation, isolation and analysis of emerging and classical pharmaceutical compounds. Mr. Davis has an in-depth understanding of the drug development process from molecule to market.

Preformulations/Formulation Development
Brian McMillan, B.A. Biochemistry, Formulation Development
Mr. McMillan is a 1989 graduate of Ohio State University with a degree in biochemistry where he also majored in the College of Pharmacy. He has seventeen years of relevant experience in the pharmaceutical development arena. He began his professional career at Roxane Laboratories in Columbus, Ohio as a methods development chemist and eventually moved into formulation development and concentrated on solid and semi-solid ANDA and NDA product development. After eight and a half years at Roxane, he joined Bausch and Lomb Pharmaceuticals in Tampa, Florida as a formulation research chemist and worked on a wide range of ANDA and NDA ophthalmic and nasal medications. While at Bausch and Lomb Mr. McMillan played a lead role in the development of Retisert™, which was approved in April 2005. Retisert™ (fluocinolone acetonide intravitreal implant 0.59mg), is a sterile implant (micro-tablet), designed to release fluocinolone acetonide locally to the posterior segment of the eye. Retisert™ is the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Prior to joining CoreRx, Inc., Mr. McMillan was at MDS Pharma services in Tampa where he worked as a manager of formulation development. In this capacity he worked closely with clients to design and execute formulation and process development studies and was responsible for the technical transfer and scale-up of prototype formulations to client facilities. These prototype formulations included IND, NDA, and ANDA development of various dosage forms including but not limited to tablets (IR, MR, SR, micro-tablets), capsules, creams, suspensions, ointments, gels, lotions, ophthalmics, and parenterals (IV and IM).

Manufacturing/Engineering
Mark J. Licarde, Manufacturing
Mr. Licarde has an A.S. in business systems technology.  He is a very resourceful individual with more than 25 years in the manufacturing industry, which includes more than 15 years experience in cGMP pharmaceutical manufacturing facilities.  He started his pharmaceutical career with Bristol Myers Squibb as a maintenance mechanic and soon advanced into technical procurement and inventory management.  Later in his career, he held the position of manufacturing supervisor at UDL Laboratories (Mylan). Mr. Licarde has been employed by MDS Pharma Services, Tampa (MDSPS), for 8 years.  As one of the original 12 employees of this company, he played a key role in the start up of this CRO facility. Through his tenure with MDSPS, he has held various positions within the company to include process/systems validation technician and manufacturing supervisor. In addition to his technical and management skills, his expertise incorporates a thorough working knowledge of manufacturing and packaging processes for solids, semi solids and liquids, business development, project quotes, technical writing, equipment maintenance, and design and implementation of preventative maintenance and calibration programs.

Saurabh (Rob) Trivedi, BS Engineering, Manufacturing
Mr. Trivedi holds a BS in engineering from NJIT (NCE). He has 13+ years of experience in the pharmaceutical industry as well as CRO facilities. He started his career as a building automation/operations engineer at Schering-Plough and was involved with all aspects of operations, facilities, clean rooms, production, utilities, automated systems, and engineering. Moving over to the manufacturing world at Schering-Plough, Mr. Trivedi impacted the tablet coating department, utilizing his knowledge from his previous position as an operations engineer. His knowledge of the manufacturing process combined with the engineering background led to his being promoted to special projects supervisor. In this role, Mr. Trivedi was the manufacturing representative for a new $80MM manufacturing facility built at the Kenilworth, NJ site headquarters for Schering-Plough. He was involved in the designing, specifying, and selection of coating and HSG manufacturing equipment, CIP and USP systems, and all other associated systems and supporting equipment. Mr. Trivedi played a key role in the validation of the aforementioned items in order to meet FDA timelines. Documentation development and execution consisted of IQ/OQ/PQ protocols, SOPs, implementation plans, SFATs, FATs, SATs, regression testing, computer system validation plans, and test summary reports. Mr. Trivedi joined MDS Pharma Services (CRO), in January 2004 as the manufacturing manager and is knowledgeable in manufacturing various dosage forms with a vast working knowledge of FDA, GMP, and CFR guidelines. He provided guidance and support for the daily functions of the manufacturing department.